1
|
Johnson ME and Howerth EW: Survivin: a
bifunctional inhibitor of apoptosis protein. Vet Pathol.
41:599–607. 2004.
|
2
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997.
|
3
|
Fujitani K: Overview of adjuvant and
neoadjuvant therapy for resectable gastric cancer in the East. Dig
Surg. 30:119–129. 2013.
|
4
|
Raffo AJ, Kim AL and Fine AL: Formation of
nuclear Bax/p53 complexes is associated with chemotherapy induced
apotosis. Oncogene. 19:6216–6228. 2000.
|
5
|
Blanc C, Deveraux QL, Krajewski S, et al:
Caspase-3 is essential for procaspase-9 processing and
cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer
Res. 60:4386–4390. 2000.
|
6
|
Sasaki CY, Lin HC and Passaniti A:
Expression of E-cadherin reduces bcl-2 expression and increases
sensitivity to etoposide-induced apoptosis. Int J Cancer.
86:660–666. 2000.
|
7
|
Yang LY and Trujillo JM: Biological
Characterisation of Multidrug-resistant Human Colon Carcinoma
Sublines Induced/Selected by Two Methods. Cancer Res. 50:3218–3225.
1990.
|
8
|
Vandier D, Calvez V, Massade L, et al:
Transactivation of the metallothionein promoter in
cisplatin-resistant cancer cells: a specific gene therapy strategy.
J Natl Cancer Inst. 92:642–647. 2000.
|
9
|
Kotoh S, Naito S, Yokomizo A, et al:
Increased expression of DNA topoisomerase I gene and collateral
sensitivity to camptothecin in human cisplatin-resistant bladder
cancer cells. Cancer Res. 54:3248–3252. 1994.
|
10
|
Godwin AK, Meister A, O’Dwyer PJ, et al:
High resistance to cisplatin in human ovarian cancer cell lines is
associated with marked increase of glutathione synthesis. Proc Natl
Acad Sci USA. 89:3070–3074. 1992.
|
11
|
Hammond JR, Johnstone RM and Gros P:
Enhanced efflux of [3H]vinblastine from Chinese hamster ovary cells
transfected with a full-length complementary DNA clone for the mdr1
gene. Cancer Res. 49:3867–3871. 1989.
|
12
|
Goldie JH and Coldman AJ: The Genetic
Origin of Drug Resistance in Neoplasms: Implications for Systemic
Therapy. Cancer Res. 44:3643–3653. 1984.
|
13
|
Goldie JH: Drug Resistance in Cancer: A
Perspective. Cancer Metastasis Rev. 20:63–68. 2001.
|
14
|
Shen X, Zheng JY, Shi H, et al: Survivin
knockdown enhances gastric cancer cell sensitivity to radiation and
chemotherapy in vitro and in nude mice. Am J Med Sci. 344:52–58.
2012.
|
15
|
Zheng WE, Chen H, Yuan SF, et al:
Overexpression of βIII-tubulin and survivin associated with drug
resistance to docetaxel-based chemotherapy in advanced gastric
cancer. J BUON. 17:284–290. 2012.
|
16
|
Wenying Z, Zhaoning J, Zhimin Y, et al:
Survivin siRNA inhibits gastric cancer in nude mice. Cell Biochem
Biophys. 62:337–341. 2012.
|
17
|
Ikeguchi M, Nakamura S and Kaibara N:
Quantitative analysis of expression levels of bax, bcl-2, and
survivin in cancer cells during cisplatin treatment. Oncol Rep.
9:1121–1126. 2002.
|
18
|
Cregan IL, Dharmarajan AM and Fox SA:
Mechanisms of cisplatin-induced cell death in malignant
mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs)
and caspases. Int J Oncol. 42:444–452. 2013.
|
19
|
Bertazza L, Mocellin S, Marchet A, et al:
Survivin gene levels in the peripheral blood of patients with
gastric cancer independently predict survival. J Transl Med.
7:1112009.
|
20
|
Krieg A, Baseras B, Tomczak M, et al: Role
of survivin as prognostic and clinicopathological marker in gastric
cancer: a meta-analysis. Mol Biol Rep. 40:5501–5511. 2013.
|